Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-03-31): -6.64%.
RETURN ON ASSETS (ROA)
N/A
RETURN ON ASSETS (ROA) AVG TTM
-14.72%
RETURN ON ASSETS (ROA) AVG 3Y
-16.00%
RETURN ON ASSETS (ROA) AVG 5Y
-18.82%
RETURN ON ASSETS (ROA) AVG 10Y
-10.35%
RETURN ON ASSETS (ROA) AVG 15Y
-0.56%
RETURN ON ASSETS (ROA) AVG 20Y
1.90%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lifecore Biomedical, Inc.
Market Cap
$243.81M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$243.66M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$243.34M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$244.64M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$240.82M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$240.66M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$240.09M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$247.93M
Return on Assets (ROA)
29.16%
TTM Avg
-1.71%
3Y Avg
-34.07%
5Y Avg
-33.80%
Market Cap
$248.98M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | $243.81M | N/A | -14.72% | -16.00% | -18.82% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | -244.25% | -369.36% | -230.97% | -157.86% |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | -187.80% | -213.40% | -188.65% | -151.14% |
| Invivyd, Inc. (IVVD)vs › | $244.64M | -49.04% | -75.08% | -74.95% | -71.96% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.82M | -8.48% | -16.43% | -20.20% | -32.31% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.66M | -114.79% | -67.19% | -63.94% | -45.91% |
| InflaRx N.V. (IFRX)vs › | $240.09M | -23.88% | -71.64% | -51.89% | -47.09% |
| Q32 Bio Inc. (QTTB)vs › | $247.93M | 29.16% | -1.71% | -34.07% | -33.80% |
| Century Therapeutics, Inc. (IPSC)vs › | $248.98M | -38.25% | -20.05% | -26.23% | -29.50% |
| High Tide Inc. (HITI)vs › | $237.25M | -8.99% | -7.90% | -14.69% | -13.78% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -13.26% |
| 2025-05-25 | -16.18% |
| 2024-05-26 | 4.73% |
| 2023-05-28 | -39.27% |
| 2022-05-29 | -42.49% |
| 2021-05-31 | -6.42% |
| 2020-05-31 | -7.06% |
| 2019-05-31 | 0.41% |
| 2018-05-31 | 6.14% |
| 2017-05-31 | 2.96% |
| 2016-05-31 | -3.39% |
| 2015-05-31 | 3.91% |
| 2014-05-31 | 6.10% |
| 2013-05-31 | 7.76% |
| 2012-05-31 | 4.57% |
| 2011-05-31 | 1.90% |
| 2010-05-31 | 1.99% |
| 2009-05-31 | 5.06% |
| 2008-05-31 | 8.99% |
| 2007-05-31 | 20.65% |
| 2006-05-31 | 7.27% |
| 2005-05-31 | 5.40% |
| 2004-05-31 | 3.12% |
| 2003-05-31 | 0.00% |
| 2002-10-31 | -1.38% |
| 2001-10-31 | -15.64% |
| 2000-10-31 | -3.23% |
| 1999-10-31 | -6.88% |
| 1998-10-31 | -6.84% |
| 1997-10-31 | -17.13% |
